FDA clears at-home start dose for Alzheimer's drug Leqembi
The FDA has cleared Eisai and Biogen's Leqembi Iqlik subcutaneous injection as a starting dose, removing the need for regular infusion clinic visits.
Newsletters and Deep Dive digital magazine
The FDA has cleared Eisai and Biogen's Leqembi Iqlik subcutaneous injection as a starting dose, removing the need for regular infusion clinic visits.
Amgen's Lumykras will no longer be funded by the Cancer Drugs Fund for KRAS-mutated lung cancer, says NHS reimbursement authority NICE.
Boehringer Ingelheim has won the first European approval for its new idiopathic pulmonary fibrosis (IPF) therapy, Jascayd, in the UK.
Vera Therapeutics has won FDA approval for Trutakna, a BAFF/APRIL inhibitor for IgAN that will compete with Otsuka's recently-launched Voyxact.
Women with endometriosis in England could be offered simple non-invasive tests for diagnosis of their condition, rather than a surgical procedure.
Editor's Picks
Newsletters and Deep Dive
digital magazine